Patheon wins 2010 Lilly Sustained Supplier Award

RESEARCH TRIANGLE PARK, NC, May 4 /CNW/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that its facility in Bourgoin, France has been awarded a 2010 Lilly Sustained Supplier Award. The coveted Lilly Sustained Supplier Award is given annually to a few global suppliers that have delivered continued exemplary quality, speed, service, or cost reduction in support of Lilly's corporate priorities.

"It is a great honor to be recognized by Eli Lilly and Company two years in a row as it demonstrates the trust built between our companies. This award is especially meaningful as it illustrates that Lilly values our commitment to providing quality, excellence and superior customer service to help them reach their goals," said Wes Wheeler, Patheon Chief Executive Officer.

In 2009, Patheon's facility in Bourgoin, France received Lilly's Supplier Award for Excellence, recognizing it as an outstanding supplier and business partner. It is a prestigious award to receive, as companies must demonstrate continued high performance.

ABOUT PATHEON

Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

%SEDAR: 00001700E

For further information: Patheon Contacts: Wes Wheeler, President & Chief Executive Officer, Tel: [phone], Email: [email protected]; Eric Evans, Chief Financial Officer, Tel: [phone], Email: [email protected]; Wendy Wilson, Investor Relations and Corporate Communications, Tel: [phone], Email: [email protected]